Cargando…

Gene expression profiling in understanding the molecular pathogenesis of and response to canakinumab therapy in traps

Detalles Bibliográficos
Autores principales:	Gattorno, M, Torene, R, Lachmann, H, Obici, L, Meini, A, Tormey, V, Caorsi, R, Baeriswyl, L, Affentranger, U, Starck-Schwertz, S, Letzkus, M, Hartmann, N, Abrams, K, Nirmala, N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190974/ http://dx.doi.org/10.1186/1546-0096-12-S1-P138

Ejemplares similares

Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome
por: Torene, Rebecca, et al.
Publicado: (2017)

OR10-006 - Canakinumab in patients with TRAPS
por: Lachmann, HJ, et al.
Publicado: (2013)

Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study
por: Gattorno, Marco, et al.
Publicado: (2017)

Canakinumab treatment in patients with active recurrent or chronic TNF-receptor associated syndrome (TRAPS): Efficacy and safety results from a proof of concept study
por: Lachmann, H, et al.
Publicado: (2015)

Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases
por: Papa, Riccardo, et al.
Publicado: (2020)

PW02-021 - SAA1 is the strongest predictor of AA in TRAPS
por: Obici, L, et al.
Publicado: (2013)

Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
por: Caorsi, R, et al.
Publicado: (2011)

P02-024 - Clinical impact of V198M mutation in NLRP3 gene
por: Caorsi, R, et al.
Publicado: (2013)

The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age
por: Caorsi, Roberta, et al.
Publicado: (2013)

OR10-005 - Treatment responses in TRAPS: Eurofever/ Eurotraps
por: Lachmann, HJ, et al.
Publicado: (2013)

PW02-008 - TRAPS in the real world: an international registry
por: Lachmann, HJ, et al.
Publicado: (2013)

PReS-FINAL-2330: Canakinumab treatment in patients with HIDS
por: Antón, J, et al.
Publicado: (2013)

Gene expression profiling of immunomagnetically separated cells directly from stabilized whole blood for multicenter clinical trials
por: Letzkus, Martin, et al.
Publicado: (2014)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

PReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy
por: Nirmala, N, et al.
Publicado: (2013)

Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS
por: Kalabus, J, et al.
Publicado: (2015)

Genes responding to Canakinumab therapy in SJIA are -inversely - disregulated in adult onset Still's disease
por: Brachat, A, et al.
Publicado: (2015)

Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
por: Wulffraat, NM, et al.
Publicado: (2014)

Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab
por: Brogan, P, et al.
Publicado: (2015)

OR7-005 – Canakinumab in childhood colchicine resistant FMF
por: Hashkes, PJ, et al.
Publicado: (2013)

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
por: Bader-Meunier, B, et al.
Publicado: (2011)

Impact of mevalonate kinase deficiency (MKD) on the quality of life in children and young adults: a national multicentre study
por: Federici, Silvia, et al.
Publicado: (2011)

Canakinumab for the treatment of different refractory autoinflammatory disorders
por: Grein, Ingrid HR, et al.
Publicado: (2014)

PReS-FINAL-2169: Exposure-response modeling of canakinumab in the avoidance of flares in children with systemic juvenile idiopathic arthritis
por: Xiong, Y, et al.
Publicado: (2013)

Canakinumab and Lung Cancer: Intriguing, but Is It Real?
por: Chabner, Bruce A., et al.
Publicado: (2018)

Treatment of refractory Yao syndrome with canakinumab
por: Brailsford, Caroline J., et al.
Publicado: (2022)

PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients
por: Quartier, P, et al.
Publicado: (2013)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome
por: Elmi, Abdulkadir A., et al.
Publicado: (2019)

The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry
por: Lachmann, H J, et al.
Publicado: (2014)

Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
por: Brachat, Arndt H., et al.
Publicado: (2017)

PW01-015 – Canakinumab in adults with colchicin resistant FMF
por: Gül, A, et al.
Publicado: (2013)

PW01-012 – Canakinumab in patients with FMF
por: Ugurlu, S, et al.
Publicado: (2013)

Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015)

Treatment of systemic-onset juvenile arthritis with canakinumab
por: Peitz, Joachim, et al.
Publicado: (2015)

Canakinumab and cardiovascular outcomes: results of the CANTOS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Canakinumab in a subgroup of patients with COVID-19
por: Ucciferri, Claudio, et al.
Publicado: (2020)

Canakinumab for refractory RA: a case report
por: Marketos, Nikolaos, et al.
Publicado: (2018)

PW02-041 - Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_g7i6n1eah3c9sdre70ihnfpo23